Despite its prevalence in the aged population, the clinical management of abdominal aortic aneurysm (AAA) is currently lacking effective tools for risk stratification and follow-up planning. 1 Indeed, referral to surgical treatment, which remains the only therapeutic option for AAA, is based only on the estimation of the AAA diameter, although there is evidence that even small aneurysms can rupture, while large aneurysms may remain stable for a long time. 1 Further to clinical judgement, based on the ability to control traditional cardiovascular risk factors in the individual patient, including arterial hypertension, diabetes, smoking and dyslipidaemia, no other clinical or biohumoral variable has been clearly demonstrated to be able to predict the risk of AAA or to guide the surveillance of patients with established disease. 1 In the current issue of the journal, Memon and colleagues present the results of their search for circulating biomarkers of AAA diameter and growth. In their case-control study, the authors compare 134 men aged 65 years who were diagnosed with AAA within a screening programme at a single Swedish centre with 136 screened men with aortic diameter less than 30 mm, matched for comorbidities and time of sampling. 2 They performed a protein profiling using Proseek Multiplex CVD III 96Â96 panel, quantifying a large set of proteins involved in multiple different cardiovascular pathways. 3 They found that 21 proteins associated with proteolysis, oxidative stress, lipid metabolism and inflammation were significantly increased, whereas levels of paraoxonase 3, associated with high-density lipoprotein metabolism, were decreased in AAA patients. Among several proteins which were differently concentrated in the plasma of cases versus controls, the combination of growth/differentiation factor 15 (GDF-15; a cytokine regulating inflammatory pathways and cell repair and growth) and cystatin B (CSTB; an inhibitor of cathepsin L, possibly involved in vascular remodelling and atherogenesis) had the best diagnostic potential. Importantly, the authors also reported that circulating levels of myeloperoxidase (a peroxydase enzyme linked to atherosclerosis and plaque vulnerability) were significantly associated with faster AAA growth at follow-up.
The current approach to the clinical management of patients with suspected or definite AAA, which does not rely on the assessment of circulating biomarkers, is thus challenged by the authors. Still, a couple of questions may rise. First, is there a real need for circulating biomarkers for diagnostic purposes? The answer is probably no, as echography is a simple, powerful and reproducible tool which is also able to provide information about some morphological characteristics of AAA (e.g. fusiform vs. saccular), with possible impact on the timing of surgical referral. Furthermore, many developed countries such as the USA, UK and Sweden have established national screening programmes based mostly on ultrasonography. 4 Second, is there a real need for circulating biomarkers for prognostic purposes? Probably yes, in order to improve our current prediction of the growth rate, to aid in follow-up planning and to select patients for surgery. The finding that myeloperoxidase is associated with an increase in AAA diameter is plausible, given its role in the pathophysiology of atherosclerosis and of vascular damage, and has some clinical interest. Still, before a novel biomarker can be proposed for clinical use, it should be validated over clinical judgement, including the combined assessment of traditional cardiovascular risk factors and baseline AAA diameter.
The method used by the authors to identify potential biomarkers for AAA is also noteworthy, as they employ a wide panel of 91 'cardiovascular-specific proteins', which are considered for an untargeted proteomic analysis. While this approach may be, to some extent, unbiased from current knowledge about the pathophysiological mechanisms of vascular damage and remodelling, it is lacking, on the other hand, a clear experimental hypothesis. Furthermore, each of the biomarkers identified by the authors as linked to the presence and growth of AAA is generally reflecting the processes of inflammation and atherogenesis, 5 as demonstrated by the low specificity (52% vs. 80% sensitivity) of the combination of GDF-15 and CSTB for the diagnosis of AAA. They may therefore be associated with the involvement of other vascular districts, such as the intracranial and coronary arterial trees (as supported, for example, by the higher prevalence of cardiovascular diseases in AAA vs. non-AAA patients in the present study, 36% vs. 29%).
Several biomarkers have been proposed in recent years for the clinical management of AAA. 6, 7 However, there are currently no specific laboratory markers for disease screening, monitoring and for therapeutic decision-making. The paper by Memon and colleagues represents a step forward, but further larger studies are needed to validate the effectiveness and costeffectiveness of the use of circulating biomarkers in AAA, for example by testing the value of serial assessment and the predictive value in patients with normal abdominal artery diameter at baseline evaluation.
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